Laforin confers cancer resistance to energy deprivation-induced apoptosis

16Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

A long-standing but poorly understood observation in experimental cancer therapy is the heterogeneity in cancer susceptibility to energy deprivation. Here, we show that the hexose kinase inhibitor 2-deoxyglucose (2-dG) preferentially kills cancer cells with defective laforin expression and significantly increases the survival of mice with aggressive lymphoma due to a genetic defect of the laforin-encoding Epm2a gene. Normal cells from Epm2a -/- mice also had greatly increased susceptibility to 2-dG. Thus, laforin is a novel regulator for cellular response to energy deprivation and its defects in cancer cells may be targeted for cancer therapy. ©2008 American Association for Cancer Research.

Cite

CITATION STYLE

APA

Wang, Y., Liu, Y., Wu, C., McNally, B., Liu, Y., & Zheng, P. (2008). Laforin confers cancer resistance to energy deprivation-induced apoptosis. Cancer Research, 68(11), 4039–4044. https://doi.org/10.1158/0008-5472.CAN-07-6314

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free